High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of ...

Discover the groundbreaking research combining DNase I with CAR T-cell therapy to enhance cancer treatment efficacy, suppress ...

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase ...

StudyFirst Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach 21.11.2024 / ...

The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute ...

The survival rate among those with lung cancer has improved by more than a quarter in the last five years, according to a new ...

Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma patients. Cytokine release syndrome occurred in 70% of patients, with lower ...

rates over historical data for bendamustine plus rituximab (Rituxan; BR) in patients with previously untreated mantle cell lymphoma (MCL), according to data from a phase 2 trial (NCT03311126) ...

Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...

Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from ...

My experience with non-Hodgkin lymphoma taught me to be grateful for the people I love and who love me. When a group of people told me my non-Hodgkin lymphoma cure was a miracle, I realized it was ...

This is despite the study having ended without an overall survival benefit – the gold ... is the largest completed trial on T-cell therapy on any solid tumour. “We are proud of the fact ...